Shots:

• Samsung Bioepis to receive $100M up front- up to $210M development- regulatory and commercial milestones and will be responsible for the development and supply of both the products. Biogen to get exclusive commercialization rights for two ophthalmology biosimilars- SB11 referencing Lucentis and SB15 referencing Eylea in the US- Canada- Europe- Japan and Australia
• Additionally- Biogen will get exclusive right to commercialize anti-TNF portfolio including Benepali (etanercept)- Flixabi (infliximab) & Imraldi (adalimumab) in exchange for royalties on sales in China and acquires an option for extending its existing commercial agreement with Samsung Bioepis for anti-TNF portfolio in EU
• The transaction is expected to be closed in Q4’19. Benapali- Flixabi & Imraldi are the biosimilars referencing Enbrel- Remicade & Humira indicated to treat RA- PsA- axSpA and other autoimmune diseases respectively

Click here to­ read full press release/ article 

| Ref: Biogen | Image: Biogen